Cargando…
Regulation of Molecular Targets in Osteosarcoma Treatment
The most prevalent malignant bone tumor, osteosarcoma, affects the growth plates of long bones in adolescents and young adults. Standard chemotherapeutic methods showed poor response rates in patients with recurrent and metastatic phases. Therefore, it is critical to develop novel and efficient targ...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604206/ https://www.ncbi.nlm.nih.gov/pubmed/36293439 http://dx.doi.org/10.3390/ijms232012583 |
_version_ | 1784817755246034944 |
---|---|
author | Celik, Betul Cicek, Kader Leal, Andrés Felipe Tomatsu, Shunji |
author_facet | Celik, Betul Cicek, Kader Leal, Andrés Felipe Tomatsu, Shunji |
author_sort | Celik, Betul |
collection | PubMed |
description | The most prevalent malignant bone tumor, osteosarcoma, affects the growth plates of long bones in adolescents and young adults. Standard chemotherapeutic methods showed poor response rates in patients with recurrent and metastatic phases. Therefore, it is critical to develop novel and efficient targeted therapies to address relapse cases. In this regard, RNA interference technologies are encouraging options in cancer treatment, in which small interfering RNAs regulate the gene expression following RNA interference pathways. The determination of target tissue is as important as the selection of tissue-specific promoters. Moreover, small interfering RNAs should be delivered effectively into the cytoplasm. Lentiviral vectors could encapsulate and deliver the desired gene into the cell and integrate it into the genome, providing long-term regulation of targeted genes. Silencing overexpressed genes promote the tumor cells to lose invasiveness, prevents their proliferation, and triggers their apoptosis. The uniqueness of cancer cells among patients requires novel therapeutic methods that treat patients based on their unique mutations. Several studies showed the effectiveness of different approaches such as microRNA, drug- or chemotherapy-related methods in treating the disease; however, identifying various targets was challenging to understanding disease progression. In this regard, the patient-specific abnormal gene might be targeted using genomics and molecular advancements such as RNA interference approaches. Here, we review potential therapeutic targets for the RNA interference approach, which is applicable as a therapeutic option for osteosarcoma patients, and we point out how the small interfering RNA method becomes a promising approach for the unmet challenge. |
format | Online Article Text |
id | pubmed-9604206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96042062022-10-27 Regulation of Molecular Targets in Osteosarcoma Treatment Celik, Betul Cicek, Kader Leal, Andrés Felipe Tomatsu, Shunji Int J Mol Sci Review The most prevalent malignant bone tumor, osteosarcoma, affects the growth plates of long bones in adolescents and young adults. Standard chemotherapeutic methods showed poor response rates in patients with recurrent and metastatic phases. Therefore, it is critical to develop novel and efficient targeted therapies to address relapse cases. In this regard, RNA interference technologies are encouraging options in cancer treatment, in which small interfering RNAs regulate the gene expression following RNA interference pathways. The determination of target tissue is as important as the selection of tissue-specific promoters. Moreover, small interfering RNAs should be delivered effectively into the cytoplasm. Lentiviral vectors could encapsulate and deliver the desired gene into the cell and integrate it into the genome, providing long-term regulation of targeted genes. Silencing overexpressed genes promote the tumor cells to lose invasiveness, prevents their proliferation, and triggers their apoptosis. The uniqueness of cancer cells among patients requires novel therapeutic methods that treat patients based on their unique mutations. Several studies showed the effectiveness of different approaches such as microRNA, drug- or chemotherapy-related methods in treating the disease; however, identifying various targets was challenging to understanding disease progression. In this regard, the patient-specific abnormal gene might be targeted using genomics and molecular advancements such as RNA interference approaches. Here, we review potential therapeutic targets for the RNA interference approach, which is applicable as a therapeutic option for osteosarcoma patients, and we point out how the small interfering RNA method becomes a promising approach for the unmet challenge. MDPI 2022-10-20 /pmc/articles/PMC9604206/ /pubmed/36293439 http://dx.doi.org/10.3390/ijms232012583 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Celik, Betul Cicek, Kader Leal, Andrés Felipe Tomatsu, Shunji Regulation of Molecular Targets in Osteosarcoma Treatment |
title | Regulation of Molecular Targets in Osteosarcoma Treatment |
title_full | Regulation of Molecular Targets in Osteosarcoma Treatment |
title_fullStr | Regulation of Molecular Targets in Osteosarcoma Treatment |
title_full_unstemmed | Regulation of Molecular Targets in Osteosarcoma Treatment |
title_short | Regulation of Molecular Targets in Osteosarcoma Treatment |
title_sort | regulation of molecular targets in osteosarcoma treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604206/ https://www.ncbi.nlm.nih.gov/pubmed/36293439 http://dx.doi.org/10.3390/ijms232012583 |
work_keys_str_mv | AT celikbetul regulationofmoleculartargetsinosteosarcomatreatment AT cicekkader regulationofmoleculartargetsinosteosarcomatreatment AT lealandresfelipe regulationofmoleculartargetsinosteosarcomatreatment AT tomatsushunji regulationofmoleculartargetsinosteosarcomatreatment |